



24024

PATENT TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this INFORMATION DISCLOSURE STATEMENT is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231, on this 3rd day of August, 2001.

Typed or Printed name of person signing this certificate:

Signed: Wendy A. Frick  
Wendy A. Frick

RECEIVED

AUG 07 2001

TECH CENTER 1600/2900

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	)	Examiner: Hunt, J.
Kaumaya, et al.	)	
	)	
Serial No.: 09/632,036	)	Art Unit: 1642
	)	
Filed: August 3, 2000	)	
	)	
For: <b>POLYPEPTIDES AND</b>	)	Attorney Docket No.: 18525/04011
<b>POLYNUCLEOTIDES FOR</b>	)	
<b>ENHANCING IMMUNE REACTIVITY</b>	)	
<b>TO HER-2 PROTEIN</b>	)	

Assistant Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

The information enclosed and cited on the accompanying form PTO-1449 is hereby submitted in compliance with 37 CFR §§1.56, 1.97 and 1.98 for consideration by the Examiner in connection with the application.

Respectfully submitted,

Date:

August 3, 2001

By:

Pamela A. Docherty  
Pamela A. Docherty, Reg. No. 40,591  
(216) 622-8416



RECEIVED

AUG 07 2001

TECH CENTER 1600/2900 Page 1 of 1

Subst. Form PTO-1449

Atty. Docket No.: 18525/04011

Serial No.: 09/632,036

APPLICANT'S INFORMATION  
DISCLOSURE STATEMENT

Applicant: Kaumaya, et al.

Filing Date: August 3, 2000

Group: 1642

## U.S. PATENT DOCUMENTS

Initial*		Document No.	Date	Name	Class	Subcl.	Filing Date
	AA	5,601,989	February 11, 1997	Cheever, et al.			May 31, 1994
	AB	5,726,023	March 10, 1998	Cheever, et al.			Jun. 6, 1995
	AC	5,773,230	June 30, 1998	Cheever, et al.			Jun. 5, 1995
	AD	5,801,005	September 1, 1998	Cheever, et al.			Mar. 31, 1995
	AE	5,840,525	November 24, 1998	Vandlen, et al.			May 31, 1995
	AF	5,869,445	February 9, 1999	Cheever, et al.			Apr. 1, 1996
	AG	5,876,712	March 2, 1999	Cheever, et al.			Jun. 6, 1995
	AH	6,015,567	January 18, 2000	Hudziak, et al.			Apr. 14, 1995
	AI	6,075,122	June 13, 2000	Cheever, et al.			Jun. 6, 1995
	AJ	6,165,464	December 26, 2000	Hudziak, et al.			Mar. 17, 1998

## FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Subcl.	Translation?
	AK						
	AL						
	AM						
	AN						
	AO						

## OTHER PRIOR ART

AP	Abstract P752, "Peptide Vaccine Strategies for Immunotherapy of HER-2/NEU Overexpressing Cancers" by Dakappagari, et al., 16 <sup>th</sup> American Peptide Symposium, Jun 26 - July 1, 1999, Minneapolis, Minnesota.
AQ	Abstract P442, "Biological Effects of Peptide Antibodies Raised to HER-2/neu. Implications for Therapy of Human Breast Cancer" by Woodbine, et al., The 1997 American Peptide Symposium, June 14-19, 1997, Nashville, Tennessee.
AR	Abstract MS009, "Peptide Vaccine Strategy for Immunotherapy of Human Breast Cancer Using HER-2/neu Oncogene" by Woodbine, et al., Fourteenth American peptide Symposium, June 18-23, 1995, Columbus, Ohio.
AS	"Prevention of Mammary Tumors with a Chimeric HER-2 B-cell Epitope Peptide Vaccine" by Dakappagari, et al., <i>Cancer Research</i> , 60, 3782-3789, July 15, 2000.
AT	"De Novo" Engineering of Peptide Immunogenic and Antigenic Determinants as Potential Vaccines" by Kaumaya, et al., <i>Peptides: Design, Synthesis and Biological Activity</i> , Channa Basava and G.M. Anantharamaiah Editors, 1994, Birkäuser Boston.

Examiner:

Date Considered:

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.